These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 10087562)

  • 1. Torsade de pointes ventricular tachycardia during low dose intermittent dobutamine treatment in a patient with dilated cardiomyopathy and congestive heart failure.
    Vecchia L; Ometto R; Finocchi G; Vincenzi M
    Pacing Clin Electrophysiol; 1999 Feb; 22(2):397-9. PubMed ID: 10087562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Torsade de pointes induced by intravenous and long-term oral amiodarone therapy in a patient with dilated cardiomyopathy.
    Yamada S; Kuga K; Yamaguchi I
    Jpn Circ J; 2001 Mar; 65(3):236-8. PubMed ID: 11266201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Torsade de pointes complicating drug treatment of low-malignant forms of arrhythmia: four cases reports.
    Faber TS; Zehender M; Van de Loo A; Hohnloser S; Just H
    Clin Cardiol; 1994 Apr; 17(4):197-202. PubMed ID: 8187370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
    Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
    Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amiodarone-induced torsade de pointes in a child with dilated cardiomyopathy.
    Silvetti MS; Drago F; Bevilacqua M; Ragonese P
    Ital Heart J; 2001 Mar; 2(3):231-6. PubMed ID: 11305536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dobutamine on plasma potassium in congestive heart failure secondary to idiopathic or ischemic cardiomyopathy.
    Goldenberg IF; Olivari MT; Levine TB; Cohn JN
    Am J Cardiol; 1989 Apr; 63(12):843-6. PubMed ID: 2929441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin-induced acquired long QT syndrome with torsades de pointes and myocardial injury in a patient with dilated cardiomyopathy and rectal cancer.
    Chang RY; Lee MY; Kan CB; Hsu WP; Hsiao PC
    J Chin Med Assoc; 2013 Aug; 76(8):466-9. PubMed ID: 23769882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy.
    Biddle TL; Benotti JR; Creager MA; Faxon DP; Firth BG; Fitzpatrick PG; Konstam MA; Krebs C; Walton L; Kershner RP
    Am J Cardiol; 1987 Jun; 59(15):1345-50. PubMed ID: 3591689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Torsades de pointes ventricular tachycardia induced by intravenous amiodarone].
    Makai A; Rudas L; Liszkai G; Fazekas T
    Orv Hetil; 2003 Feb; 144(5):241-7. PubMed ID: 12647553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amiodarone attenuates the proarrhythmic effects of dobutamine in patients with advanced congestive heart failure.
    Tsagalou EP; Gounopoulos P; Terrovitis JV; Drakos SG; Katsaros FT; Kaldara EE; Alexopoulos GP; Anastasiou-Nana MI
    Hellenic J Cardiol; 2009; 50(3):193-8. PubMed ID: 19465360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneous sequences of onset of torsade de pointes in patients with acquired prolonged repolarization: quantitative analysis of Holter recordings.
    Locati EH; Maison-Blanche P; Dejode P; Cauchemez B; Coumel P
    J Am Coll Cardiol; 1995 Jun; 25(7):1564-75. PubMed ID: 7539014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations.
    Carlsson L; Abrahamsson C; Andersson B; Duker G; Schiller-Linhardt G
    Cardiovasc Res; 1993 Dec; 27(12):2186-93. PubMed ID: 8313427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of Torsade de Pointes arrhythmias.
    Van Opstal JM; Leunissen JD; Wellens HJ; Vos MA
    Eur J Pharmacol; 2001 Jan; 412(1):67-76. PubMed ID: 11166738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Iatrogenic torsade de pointes induced by thioridazine].
    Paoloni P; Ciliberti D; Blasi N; Capone P
    Minerva Cardioangiol; 1992 Jun; 40(6):245-9. PubMed ID: 1407620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired prolongation of QT interval as a risk factor for torsade de pointes ventricular tachycardia: a narrative review for the anesthesiologist and intensivist.
    Uvelin A; Pejaković J; Mijatović V
    J Anesth; 2017 Jun; 31(3):413-423. PubMed ID: 28229241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypotension with dobutamine: beta-adrenergic antagonist selectivity at low doses of carvedilol.
    Lindenfeld J; Lowes BD; Bristow MR
    Ann Pharmacother; 1999 Dec; 33(12):1266-9. PubMed ID: 10630826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haloperidol-induced torsade de pointes.
    O'Brien JM; Rockwood RP; Suh KI
    Ann Pharmacother; 1999 Oct; 33(10):1046-50. PubMed ID: 10534216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Torsade de pointes tachycardia in a patient on dronedarone therapy.
    Huemer M; Sarganas G; Bronder E; Klimpel A; Garbe E; Haverkamp W
    Pharmacotherapy; 2015 May; 35(5):e61-5. PubMed ID: 25823967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of erythromycin-induced malignant tachyarrhythmia--torsade de pointes. A case report.
    Katapadi K; Kostandy G; Katapadi M; Hussain KM; Schifter D
    Angiology; 1997 Sep; 48(9):821-6. PubMed ID: 9313632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
    Kühlkamp V; Mermi J; Mewis C; Seipel L
    J Cardiovasc Pharmacol; 1997 Mar; 29(3):373-81. PubMed ID: 9125676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.